glp 1 investing GLP-1 Market: Novo vs Eli Lilly in $58B Showdown | Pharmint posted on the topic GLP-1 2.0: Where the Next

Retrieved from Mozaffarian, D., Agarwal, M., Aggarwal, M., et al

Pricing Disclaimer: All prices, discounts, and promotional offers mentioned were based on Oak's publicly available website as of April 2026 and are subject to change without notice

Patient-Specific Factors: Unique circumstances making GLP-1 the best choice (e.g., comorbidities, allergies)

At week 26, treatment with TOUJEO provided a mean reduction in HbA1c that met the prespecified noninferiority margin of 0.4% compared to LANTUS (Table 6)

These case studies demonstrate how the agencies criteria and jurisdictions lead to different pricing/access outcomes

doi: 10.1126/sciadv.abg4544